Intellia Therapeutics Stock Surges on Gene-Editing Trial Success

Intellia Therapeutics captured significant market attention on November 16 when the biotechnology firm unveiled groundbreaking clinical trial data for its CRISPR-based therapy, nexiguran ziclumeran (nex-z). The phase 1 study results focused on treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM), with findings simultaneously published in the prestigious New England Journal of Medicine—a strong indicator of the data’s scientific importance.

The company’s shares demonstrated considerable volatility around the announcement, trading between $13.12 and $15.20 during the presentation period. This marks the first demonstration that Intellia’s gene-editing approach can positively impact the progression of this rare but fatal condition.

In the phase 1 trial involving 36 ATTR-CM patients, half were classified as New York Read more...